Biomarkers needed to support the diagnosis of frontotemporal lobar degeneration
Neurofilament light chain (NfL) measured from a blood sample strongly correlates with the duration of the disease in frontotemporal lobar degeneration (FTLD) patients and the rate of brain atrophy, according to a new study published by the University of Eastern Finland in the Annals of Clinical and Translational Neurology.
FTLD is the second most common cause of degenerative and progressive dementing diseases in the working-age population after Alzheimer’s disease.
FTLD is divided into two subgroups based on the primary symptoms. Early symptoms of the most common form of FTLD, behavioral variant frontotemporal dementia (bvFTD), include changes in behavior, personality, and executive functions.
In the second subgroup, primary progressive aphasia (PPA), the primary symptoms are linguistic, including naming problems and problems in speech production. FTLD patients often have also concomitant motor neuron disease (FTD-MND), and there is some overlap in the neuropathology and genetic alterations between these diseases.
University of Eastern Finland
Cajanus, A., et al. (2020) Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype and prognosis. Annals of Clinical and Translational Neurology. doi.org/10.1002/acn3.51041.